Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY

Primary Investigator
Mody, Rajen
Status
OPEN TO ACCRUAL
Phase
NA
NCT Number
NCT02402244
UM Number
2015.191
Age Group
Both
Management Group
CTSU - Oncology
Oncology Group
Childhood Cancers
ID (Protocol)
6993
Secondary Protocol No
HUM00109219
Scope
Unspecified
Sponsor Type
Institutional
Disease Site
Anus
Bones and Joints
Brain and Nervous System
Breast
Cervix
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Hodgkin's Lymphoma
Ill-Defined Sites
Kaposi's Sarcoma
Kidney
Larynx
Leukemia, other
Lip, Oral Cavity and Pharynx
Liver
Lung
Lymphoid Leukemia
Melanoma, Skin
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Digestive Organ
Other Endocrine System
Other Female Genital
Other Hematopoietic
Other Male Genital
Other Respiratory and Intrathoracic Organs
Other Skin
Other Skin Excludes: Melanoma, Mycosis fungoides, Kaposi's sarcoma
Other Urinary
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Unknown Sites
Urinary Bladder
Summary
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Eligibility: Inclusion Criteria
  •   Inclusion Criteria: Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence. For patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial.
  •   Inclusion Criteria: Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
    •   Inclusion Criteria: All cancer cases with an ICD-O histologic behavior code of two ¿2¿ (carcinoma in situ) or three ¿3¿ (malignant).
    •   Inclusion Criteria: All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
    •   Inclusion Criteria: Other benign/borderline conditions include: mesoblastic nephroma, teratomas, myeloproliferative diseases including transient myeloproliferative disease, Langerhan cell histiocytosis, lymphoproliferative diseases
  •   Inclusion Criteria: Subjects must be = 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.
  •   Inclusion Criteria: All patients or their parents or legally authorized representatives must sign a written informed consent. Parents will be asked to sign a separate consent for their own bio specimen submission.